All In Biotech

Drug Trial Radar · NCT06347016

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

311

Actual

Start

Jul 23, 2024

Primary completion

Jun 17, 2026

Study completion Sep 10, 2026

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • Plozasiran InjectionDrug

    ARO-APOC3 Injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in fasting serum TG levels from baseline to Month 12 compared to placeboTime frame: Baseline, Month 12

Locations

149 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site 1

    Birmingham, Alabama

  • Research Site 2

    Mobile, Alabama

  • Research Site 3

    Beverly Hills, California

  • Research Site 4

    Canoga Park, California

  • Research Site 5

    Huntington Beach, California

  • Research Site 6

    Lincoln, California

  • Research Site 7

    Long Beach, California

  • Research Site 8

    Oxnard, California

  • Research Site 9

    Clearwater, Florida

  • Research Site 10

    North Miami, Florida

  • Research Site 11

    Sarasota, Florida

  • Research Site 12

    Lawrenceville, Georgia

  • Research Site 13

    Sugar Hill, Georgia

  • Research Site 14

    Elkhart, Indiana

  • Research Site 15

    Indianapolis, Indiana

  • Research Site 16

    South Bend, Indiana

  • Research Site 17

    Overland Park, Kansas

  • Research Site 18

    Topeka, Kansas

  • Research Site 19

    Metairie, Louisiana

  • Research Site 20

    Annapolis, Maryland

  • Research Site 21

    Jackson, Mississippi

  • Research Site 22

    Fremont, Nebraska

  • Research Site 23

    Norfolk, Nebraska

  • Research Site 24

    Morristown, New Jersey

  • Research Site 26

    New York, New York

  • Research Site 27

    Riverhead, New York

  • Research Site 25

    The Bronx, New York

  • Research Site 28

    Asheboro, North Carolina

  • Research Site 29

    Wilmington, North Carolina

  • Research Site 30

    Beavercreek, Ohio

  • Research Site 31

    Columbus, Ohio

  • Research Site 32

    Oklahoma City, Oklahoma

  • Research Site 33

    Horsham, Pennsylvania

  • Research Site 34

    Newport, Pennsylvania

  • Research Site 35

    Philadelphia, Pennsylvania

  • Research Site 36

    Philadelphia, Pennsylvania

  • Research Site 37

    Fort Mill, South Carolina

  • Research Site 38

    Greenville, South Carolina

  • Research Site 39

    Chattanooga, Tennessee

  • Research Site 40

    Fort Worth, Texas

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.